Advancis Pharmaceutical Corp., of Gaithersburg, Md., added Robert Guttendorf as vice president of preclinical research and Beth Burnside as senior director of formulation development.
Affymetrix Inc., of Santa Clara, Calif., appointed Steve Lombardi vice president of corporate development.
Cellegy Pharmaceuticals Inc., of South San Francisco, formed a female sexual health advisory board, consisting of Jennifer Berman, Susan Davis, Andre Guay, Morrie Gelfand, Jeanne Alexander and Raymond Rosen.
Crucell NV, of Leiden, the Netherlands, named Jaap Goudsmit chief scientific officer.
CuraGen Corp., of New Haven, Conn., added Tim Shannon as senior vice president of research and development and chief medical officer.
Endovasc Ltd. Inc., of Montgomery, Texas, formed its clinical advisory board, consisting of Richard Smalling, H.V. Anderson, Christie Ballantyne, Antonio Colombo, Rachelle Doody, Mark Entman, Alan Garber, James Grotta, Craig Hartley, Timothy Henry, Joel Morrisett, Chet Rees, Robert Roberts and Alan Ching Yuen Yeung.
Insmed Inc., of Richmond, Va., appointed Mary Callan vice president of corporate development.
Iomed Inc., of Salt Lake City, appointed Jessica Barrett director of product marketing.
Ixion Biotechnology Inc., of Alachua, Fla., added Albert Fosmoe as senior manager, regulatory affairs and quality assurance, and Chris Setina and Marlo Tan Walpole to its oxalate control product program.
Medarex Inc., of Princeton, N.J., added Geoffrey Nichol as senior vice president, product development.
MGI Pharma Inc., of Minneapolis, appointed Edward Mehrer to its board.